

ACOG PRACTICE BULLETIN



CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN—GYNECOLOGISTS

NUMBER 95, JULY 2008

Anemia in Pregnancy

This Practice Bulletin was developed by the ACOG Committee on Practice Bulletins—Obstetrics with the assistance of Maureen Malee, PhD, MD. The information is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

Anemia, the most common hematologic abnormality, is a reduction in the concentration of erythrocytes or hemoglobin in blood. The two most common causes of anemia in pregnancy and the puerperium are iron deficiency and acute blood loss. Iron requirements increase during pregnancy, and a failure to maintain sufficient levels of iron may result in adverse maternal–fetal consequences. The purpose of this document is to provide a brief overview of the causes of anemia in pregnancy, review iron requirements, and provide recommendations for screening and clinical management of anemia during pregnancy.

Background

Classification

The definition of *anemia* recommended by the Centers for Disease Control and Prevention is a hemoglobin (Hgb) or hematocrit (Hct) value less than the fifth percentile of the distribution of Hgb or Hct in a healthy reference population based on the stage of pregnancy. Classification derived from an iron-supplemented population lists the following levels as anemic: Hgb (g/dL) and Hct (percentage) levels below 11 g/dL and 33%, respectively, in the first trimester; 10.5 g/dL and 32%, respectively, in the second trimester; and 11 g/dL and 33%, respectively, in the third trimester (1).

Anemias may be categorized by the underlying causative mechanism, red blood cell morphology, or by whether they are inherited or acquired (see the boxes). A mechanistic approach categorizes anemias caused by decreased red blood cell production, increased red blood cell destruction, and blood loss. Decreased production may result from a lack of nutrients, such as iron, vitamin B₁₂, or folate. This lack may be a result of dietary deficiency, malabsorption, or bleeding. Bone marrow disorders or suppression, hormone deficiencies, and chronic disease or infection also may lead to decreased production. Hemolytic anemias are associated with increased destruction.

THE AMERICAN COLLEGE OF
OBSTETRICIANS AND
GYNECOLOGISTS
WOMEN'S HEALTH CARE PHYSICIANS

Anemia Classification

Acquired

- Deficiency anemia (eg, iron, vitamin B₁₂, folate)
- Hemorrhagic anemia
- Anemia of chronic disease
- Acquired hemolytic anemia
- Aplastic anemia

Inherited

- Thalassemias
- Sickle cell anemia
- Hemoglobinopathies (other than sickle cell anemia)
- Inherited hemolytic anemias

Anemias Characterized by Mechanism

Decreased red blood cell production

- Iron deficiency anemia
- Anemia associated with vitamin B₁₂ deficiency
- Folic acid deficiency anemia
- Anemia associated with bone marrow disorders
- Anemia associated with bone marrow suppression
- Anemia associated with low levels of erythropoietin
- Anemia associated with hypothyroidism

Increased red blood cell destruction

- Inherited hemolytic anemias
 - Sickle cell anemia
 - Thalassemia major
 - Hereditary spherocytosis
- Acquired hemolytic anemias
 - Autoimmune hemolytic anemia
 - Hemolytic anemia associated with thrombotic thrombocytopenic purpura
 - Hemolytic anemia associated with hemolytic uremic syndrome
 - Hemolytic anemia associated with malaria
- Hemorrhagic anemia

Anemias also may be classified by cell size. In contemporary practice, this typically is done by an automated cell counter. Macrocytic anemias are associated with a mean corpuscular volume (MCV) greater than 100 fL. Reticulocytosis also may cause an increased MCV. A

Anemias Classified by Mean Corpuscular Volume

Microcytic (MCV less than 80 fL)

- Iron deficiency anemia
- Thalassemias
- Anemia of chronic disease
- Sideroblastic anemia
- Anemia associated with copper deficiency
- Anemia associated with lead poisoning

Normocytic (MCV 80–100 fL)

- Hemorrhagic anemia
- Early iron deficiency anemia
- Anemia of chronic disease
- Anemia associated with bone marrow suppression
- Anemia associated with chronic renal insufficiency
- Anemia associated with endocrine dysfunction
- Autoimmune hemolytic anemia
- Anemia associated with hypothyroidism or hypopituitarism
- Hereditary spherocytosis
- Hemolytic anemia associated with paroxysmal nocturnal hemoglobinuria

Macrocytic (MCV greater than 100 fL)

- Folic acid deficiency anemia
- Anemia associated with vitamin B₁₂ deficiency
- Drug-induced hemolytic anemia (eg, zidovudine)
- Anemia associated with reticulocytosis
- Anemia associated with liver disease
- Anemia associated with ethanol abuse
- Anemia associated with acute myelodysplastic syndrome

Abbreviation: MCV, mean corpuscular volume

common cause of macrocytic anemia is folate deficiency. Microcytic anemias are associated with an MCV less than 80 fL. The most common cause of microcytic anemia is iron deficiency. Another common cause of microcytic anemia in certain ethnic groups is hemoglobinopathy (2).

Anemia in Pregnancy

Pregnancy is associated with physiologic changes that may complicate the diagnosis of hematologic disorders. There is an increased iron requirement during pregnancy because blood volume expands by approximately 50%

(1,000 mL), and total red blood cell mass expands by approximately 25% (300 mL) during a singleton gestation (3). The greater expansion in plasma typically is reflected by decreases in Hgb and Hct levels.

The total amount of iron in the body is determined by intake, loss, and storage (4). There are approximately 2.3 g of total body iron in women. Additional iron stores during pregnancy (approximately 1 g) support this increased red blood cell mass, the fetus and placenta, and the anticipated blood loss accompanying a vaginal delivery. When there is adequate iron to meet needs, more than 70% is classified as functional iron, and the remainder as storage iron. Of the functional iron, more than 80% is found in the red blood cell mass as hemoglobin, with the remainder in myoglobin and in respiratory enzymes (5).

Iron Deficiency Anemia

Iron deficiency can be defined as abnormal values on biochemical test results, increases in hemoglobin concentrations of more than 1 g/dL after iron treatment, or absent bone marrow iron stores as determined by a bone marrow iron smear (1). The spectrum of iron deficiency ranges from iron depletion, when stored iron is low, to iron deficient erythropoiesis, when both stored and transport iron are low, to iron deficiency anemia, when stored, transport, and functional iron are low (6).

Measurements of serum Hgb concentration or Hct are the primary screening tests for identifying anemia but are nonspecific for identifying iron deficiency. Normal iron indices are listed in Table 1. Laboratory test results characteristic of iron deficiency anemia are a microcytic, hypochromic anemia with evidence of depleted iron stores, low plasma iron levels, high total iron-binding capacity, low serum ferritin levels, and increased levels of free erythrocyte protoporphyrin.

Measurement of ferritin levels has the highest sensitivity and specificity for diagnosing iron deficiency in anemic patients (7). Levels of less than 10–15 micrograms/L confirm iron-deficiency anemia. The Centers for Disease Control and Prevention recommends screening for iron deficiency anemia in pregnant women and universal iron supplementation to meet the iron requirements

Table 1. Normal Iron Indices in Pregnancy

Test	Normal Value
Plasma iron level	40–175 micrograms/dL
Plasma total iron-binding capacity	216–400 micrograms/dL
Transferrin saturation	16–60%
Serum ferritin level	More than 10 micrograms/dL
Free erythrocyte protoporphyrin level	Less than 3 micrograms/g

of pregnancy except in the presence of certain genetic disorders, such as hemochromatosis (1, 8). The rationale is that treatment maintains maternal iron stores and may be beneficial for neonatal iron stores. The typical diet confers 15 mg of elemental iron per day. The recommended daily dietary allowance of ferrous iron during pregnancy is 27 mg, which is present in most prenatal vitamins (8). Available iron supplements are listed in Table 2. Perinatal iron supplementation is important because the typical American diet and endogenous stores are insufficient sources for the increased iron requirements during pregnancy. Sustained-release or enteric-coated preparations dissolve poorly and may be less effective.

Prevalence, Etiologies, and Risk Factors

A national study of anemia in pregnancy in the United States found a prevalence of 21.55 per 1,000 women when anemia was defined as a hemoglobin concentration less than 10 g/dL (9). The prevalence of anemia in pregnancy in non-Hispanic black women (35.38 per 1,000 women) was two times higher than that of non-Hispanic white women (18.02 per 1,000 women) (9). Teenaged mothers had the highest prevalence of anemia in pregnancy of all races (9). Prevalence data specific to iron deficiency anemia in pregnancy are limited (10). A recent report estimates that in a low income, mostly minority population, rates of iron deficiency anemia are 1.8% in the first trimester, 8.2% in the second trimester, and 27.4% in the third trimester (11).

In reproductive-aged women of all races, risk factors for iron deficiency anemia include a diet poor in iron-rich foods, such as clams, oysters, liver, beef, shrimp, turkey, enriched breakfast cereals, beans, and lentils; a diet poor in iron absorption enhancers, such as orange juice, grapefruit, strawberries, broccoli, and peppers; a diet rich in foods that diminish iron absorption, such as dairy products, soy products, spinach, coffee, and tea; pica (eating nonfood substances such as clay or laundry starch); gastrointestinal disease affecting

Table 2. Iron Supplements

Preparation	Dose
Ferrous fumarate	106 mg elemental iron per 325 mg tablet
Ferrous sulfate	65 mg elemental iron per 325 mg tablet
Ferrous gluconate	34 mg elemental iron per 300 mg tablet
Iron dextran	50 mg elemental iron per milliliter, intramuscularly or intravenously
Ferric gluconate	12.5 mg iron per milliliter, intravenously only
Iron sucrose	20 mg iron per milliliter, intravenously only

absorption; heavy menses; short interpregnancy interval; and blood loss at delivery exceeding that of an uncomplicated vaginal delivery.

Iron deficiency anemia during pregnancy has been associated with an increased risk of low birth weight, preterm delivery, and perinatal mortality (11, 12). In addition, there may be an association between maternal iron deficiency anemia and postpartum depression, with poor results in mental and psychomotor performance testing in offspring (13–15).

Macrocytic Anemia

Macrocytic anemia may be megaloblastic or nonmegaloblastic. Causes of megaloblastic anemia include folate and vitamin B₁₂ deficiency and pernicious anemia. Causes of nonmegaloblastic anemia include alcoholism, liver disease, myelodysplasia, aplastic anemia, hypothyroidism, and an increased reticulocyte count. Macrocytic anemia is characterized by an MCV greater than 100 fL. Levels greater than 115 fL are almost exclusively seen in patients with folic acid or vitamin B₁₂ deficiencies. The diagnosis may be confirmed by measurement of serum folic acid or vitamin B₁₂ levels. Measurement of red cell folate also has been proposed (16). In the United States, macrocytic anemia beginning during pregnancy is overwhelmingly caused by folic acid deficiency. It is associated with diets lacking fresh leafy vegetables, legumes, or animal proteins. During pregnancy, folic acid requirements increase from 50 micrograms to 400 micrograms per day. Treatment of pregnancy-induced folic acid deficiency should include a nutritious diet and folic acid and iron supplementation. Treatment with 1 mg of folic acid, administered orally, each day typically produces an appropriate response. Macrocytic anemia in pregnancy caused by vitamin B₁₂ (cyanocobalamin) deficiency may be encountered in women who have had a partial or total gastric resection or in women with Crohn disease. Women who have had a total gastrectomy require 1,000 micrograms of vitamin B₁₂, intramuscularly, at monthly intervals.

Clinical Considerations and Recommendations

► ***Who should be screened for anemia during pregnancy?***

All pregnant women should be screened for anemia during pregnancy. Those with iron deficiency anemia should be treated with supplemental iron, in addition to prenatal vitamins. Patients with anemia other than iron deficiency anemia should be further evaluated.

► ***When should evaluation of an asymptomatic patient with mild anemia be considered?***

Asymptomatic women who meet the criteria for anemia (Hct levels less than 33% in the first and third trimesters and less than 32% in the second trimester) should be evaluated. Living at a high altitude and tobacco abuse cause a generalized upward shift in Hgb and Hct levels, and adjustments for these potential confounders may be appropriate (17–19). Hemoglobin and Hct levels are lower in African-American women compared with white women, even after correction for income (20, 21). Thus, applying the same criteria to all women could inappropriately classify almost 30% of African-American women as iron deficient. For African-American adults, the Institute of Medicine recommends lowering the cut-off levels for Hgb and Hct by 0.8 g/dL and 2%, respectively (21, 22).

► ***How should asymptomatic pregnant women with mild to moderate anemia be evaluated?***

The initial evaluation of pregnant women with mild to moderate anemia may include a medical history, physical examination, and measurements of the complete blood count, red blood cell indices, serum iron levels, and ferritin levels. Examination of a peripheral smear is helpful for the diagnosis of hemolytic or parasitic disease. In certain ethnic groups, an Hgb electrophoresis is indicated (2). Using biochemical tests, iron deficiency anemia is defined by results of abnormal values for levels of serum ferritin, transferrin saturation, and levels of free erythrocyte protoporphyrin, along with low Hgb or Hct levels (see Table 1 and Table 3). In practice, the diagnosis of mild to moderate iron deficiency anemia is often presumptive. In patients without evidence of causes of anemia other than iron deficiency, it may be reasonable to empirically initiate iron therapy without first obtaining iron test results. When pregnant women with moderate iron deficiency anemia are given adequate iron therapy, reticulocytosis may be observed 7–10 days after iron therapy, followed by an increase in Hgb and Hct levels in subsequent weeks. Failure to respond to iron therapy should prompt further investigation and may suggest an incorrect diagnosis, coexisting disease, malabsorption (sometimes caused by the use of enteric-coated tablets or concomitant use of antacids), noncompliance, or blood loss.

► ***Are there benefits of iron supplementation for patients who are not anemic?***

Iron supplementation decreases the prevalence of maternal anemia at delivery (23). However, it is unclear

Table 3. Biochemical Tests for Diagnosis of Anemia

Test	Results Indicating Iron Deficiency Anemia	Results Indicating Thalassemia	Results Indicating Anemia of Chronic Disease
Iron level	Decreased level	Normal	Decreased level
Total iron-binding capacity	Increased capacity	Normal	Decreased capacity
Ferritin level	Decreased level	Normal	Increased level
Iron/total iron-binding capacity	Less than 18%	Normal	More than 18%

whether iron supplementation in well-nourished pregnant women who are not anemic affects perinatal outcomes. There is little evidence that iron supplementation results in morbidity beyond gastrointestinal symptoms, except in patients with hemochromatosis or certain other genetic disorders.

► ***When should transfusion be considered in the antepartum or preoperative patient?***

Transfusions of red cells seldom are indicated unless hypovolemia from blood loss coexists or an operative delivery must be performed on a patient with anemia. The need for transfusion in women with antepartum complications can be predicted in only 24% of those who ultimately require blood products (24). The most common diagnoses associated with transfusion include trauma caused by instrumented delivery, uterine atony, placenta previa, retained products of conception, placental abruption, and coagulopathy (eg, the syndrome of hemolysis, elevated liver enzymes, and low platelet count [HELLP]). The presence of these diagnoses in a patient with anemia should prompt consideration of transfusion, particularly in the presence of unstable vital signs (24).

Severe anemia with maternal Hgb levels less than 6 g/dL has been associated with abnormal fetal oxygenation, resulting in nonreassuring fetal heart rate patterns, reduced amniotic fluid volume, fetal cerebral vasodilatation, and fetal death (25, 26). Thus, maternal transfusion should be considered for fetal indications in cases of severe anemia.

► ***When should parenteral iron be used in pregnant patients? Is there a role for erythropoietin?***

Parenteral iron is used in the rare patient who cannot tolerate or will not take modest doses of oral iron. Patients with a malabsorption syndrome and severe iron deficiency anemia may benefit from parenteral therapy. Anaphylactic reactions have been reported in 1% of

patients receiving parenteral iron dextran. In comparison with patients who take iron dextran, patients who take ferrous sucrose have fewer allergic reactions (8.7 versus 3.3 allergic events per 1,000,000 doses) and a significantly lower fatality rate (31 versus 0, $P < .001$) (27). In a recent randomized trial of the use of oral versus intravenous iron sucrose for postpartum anemia, women treated with intravenous iron had significantly higher Hgb levels on days 5 and 14 than women treated with an oral supplement. However, by day 40, there was no significant difference between the Hgb levels of the two groups (28). Thus, in most clinical circumstances, oral preparations are appropriate and sufficient.

Few studies have examined the role of erythropoietin in pregnant patients with anemia. In a randomized, controlled trial that examined the time to reach the targeted Hgb value and changes in efficacy measurements, including reticulocyte count and Hct levels, the use of both parenteral iron and parenteral iron plus erythropoietin improved measured parameters. However, the use of adjuvant erythropoietin alone was associated with a significantly shorter time to the targeted hemoglobin level and improved indices (reticulocyte count, Hct levels) in less than 2 weeks after treatment was initiated. No differences in maternal–fetal safety parameters were reported (29). In contrast, a randomized trial of women with postpartum anemia showed no additional benefit of the use of erythropoietin and iron versus iron alone (30).

► ***Is there a role for autologous transfusion?***

Case reports suggest a role for autologous transfusion in patients with diagnoses placing them at high risk of symptomatic blood loss, such as placenta previa. Suggested criteria for consideration of autologous donation include an Hct level greater than 32% at 32 weeks of gestation (31). However, autologous transfusions rarely are performed, and the inability to predict the eventual need for transfusion has led to the conclusion that they are not cost-effective (32).

Summary of Recommendations and Conclusions

The following conclusion is based on good and consistent scientific evidence (Level A):

- ▶ Iron supplementation decreases the prevalence of maternal anemia at delivery.

The following recommendation and conclusions are based on limited or inconsistent scientific data (Level B):

- ▶ Iron deficiency anemia during pregnancy has been associated with an increased risk of low birth weight, preterm delivery, and perinatal mortality.
- ▶ Severe anemia with maternal Hgb levels less than 6 g/dL has been associated with abnormal fetal oxygenation resulting in nonreassuring fetal heart rate patterns, reduced amniotic fluid volume, fetal cerebral vasodilatation, and fetal death. Thus, maternal transfusion should be considered for fetal indications.

The following recommendations are based primarily on consensus and expert opinion (Level C):

- ▶ All pregnant women should be screened for anemia, and those with iron deficiency anemia should be treated with supplemental iron, in addition to prenatal vitamins.
- ▶ Patients with anemia other than iron deficiency anemia should be further evaluated.
- ▶ Failure to respond to iron therapy should prompt further investigation and may suggest an incorrect diagnosis, coexisting disease, malabsorption (sometimes caused by the use of enteric-coated tablets or concomitant use of antacids), noncompliance, or blood loss.

Proposed Performance Measure

Percentage of pregnant patients with iron deficiency anemia treated with supplemental iron in addition to prenatal vitamins

References

1. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and

Prevention. MMWR Recomm Rep 1998;47(RR-3):1–29. (Level III)

2. Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998;850:251–69. (Level II-3)
3. Pitkin RM. Nutritional influences during pregnancy. Med Clin North Am 1977;61:3–15. (Level III)
4. Bothwell TH. Overview and mechanisms of iron regulation. Nutr Rev 1995;53:237–45. (Level III)
5. Bothwell TH, Charlton RW. Iron deficiency in women. Washington, DC: The Nutrition Foundation; 1981. (Level III)
6. Baynes RD. Iron deficiency. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron metabolism in health and disease. Philadelphia (PA): W.B. Saunders; 1994. p.189–225. (Level III)
7. Ontario Association of Medical Laboratories. Guidelines for the use of serum tests for iron deficiency. Guidelines for Clinical Laboratory Practice CLP 002. North York (ON): OAML; 1995. Available at: <http://www.oaml.com/PDF/CLP002.pdf>. Retrieved April 4, 2008. (Level III)
8. Institute of Medicine (US). Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press 2002. (Level III)
9. Adebisi OY, Strayhorn G. Anemia in pregnancy and race in the United States: blacks at risk. Fam Med 2005;37:655–62. (Level III)
10. Agency for Healthcare Research and Quality. Screening for iron deficiency anemia in childhood and pregnancy: update of the 1996 U.S. Preventive Task Force review. AHRQ Publication No. 06-0590-EF-1. Rockville (MD): AHRQ; 2006. (Level III)
11. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr 2005;81:1218S–22S. (Level III)
12. Rasmussen K. Is there a causal relationship between iron deficiency or iron-deficiency anemia and weight at birth, length of gestation and perinatal mortality? J Nutr 2001;131:590S,601S; discussion 601S–603S. (Level III)
13. Tamura T, Goldenberg RL, Hou J, Johnston KE, Cliver SP, Ramey SL et al. Cord serum ferritin concentrations and mental and psychomotor development of children at five years of age. J Pediatr 2002;140:165–70. (Level II-2)
14. Corwin EJ, Murray-Kolb LE, Beard JL. Low hemoglobin level is a risk factor for postpartum depression. J Nutr 2003;133:4139–42. (Level II-3)
15. Perez EM, Hendricks MK, Beard JL, Murray-Kolb LE, Berg A, Tomlinson M, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutr 2005;135:850–5. (Level I)
16. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159:1289–98. (Level III)
17. CDC criteria for anemia in children and childbearing-aged women. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep 1989;38:400–4. (Level III)

18. Dirren H, Logman MH, Barclay DV, Freire WB. Altitude correction for hemoglobin. *Eur J Clin Nutr* 1994;48:625–32. (Level II-3)
19. Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and anemia screening. *JAMA* 1990;264:1556–9. (Level II-2)
20. Johnson-Spear MA, Yip R. Hemoglobin difference between black and white women with comparable iron status: justification for race-specific anemia criteria. *Am J Clin Nutr* 1994;60:117–21. (Level III)
21. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin differences between blacks and whites. *J Nutr* 1992;122:1417–24. (Level II-3)
22. Institute of Medicine (US). Iron deficiency anemia: recommended guidelines for the prevention, detection, and management among U.S. children and women of child-bearing age. Washington, DC: National Academy Press; 1993. (Level III)
23. Pena-Rosas JP, Viteri FE. Effects of routine oral iron supplementation with or without folic acid for women during pregnancy. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD004736. DOI: 10.1002/14651858.CD004736.pub2. (Level III)
24. Sherman SJ, Greenspoon JS, Nelson JM, Paul RH. Obstetric hemorrhage and blood utilization. *J Reprod Med* 1993;38:929–34. (Level II-2)
25. Carles G, Tobal N, Raynal P, Herculat S, Beucher G, Marret H, et al. Doppler assessment of the fetal cerebral hemodynamic response to moderate or severe maternal anemia. *Am J Obstet Gynecol* 2003;188:794–9. (Level II-3)
26. Sifakis S, Pharmakides G. Anemia in pregnancy. *Ann NY Acad Sci* 2000;900:125–36. (Level III)
27. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. *Am J Kidney Dis* 1999;33:464–70. (Level III)
28. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. *BJOG* 2006;113:1248–52. (Level I)
29. Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. *Am J Obstet Gynecol* 2001;184:662–7. (Level I)
30. Wagstrom E, Akesson A, Van Rooijen M, Larson B, Bremme K. Erythropoietin and intravenous iron therapy in postpartum anaemia. *Acta Obstet Gynecol Scand* 2007;86: 957–62. (Level I)
31. Toedt ME. Feasibility of autologous blood donation in patients with placenta previa. *J Fam Pract* 1999;48: 219–21. (Level II-3)
32. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. *N Engl J Med* 1995;332: 719–24. (Level III)

The MEDLINE database, the Cochrane Library, and ACOG's own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1985 and September 2007. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician-gynecologists were used. Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

- Level A—Recommendations are based on good and consistent scientific evidence.
- Level B—Recommendations are based on limited or inconsistent scientific evidence.
- Level C—Recommendations are based primarily on consensus and expert opinion.

Copyright © July 2008 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the Internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Requests for authorization to make photocopies should be directed to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400.

The American College of Obstetricians and Gynecologists
409 12th Street, SW, PO Box 96920, Washington, DC 20090-6920

Anemia in pregnancy. ACOG Practice Bulletin No. 95. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2008;112: 201–7.